1. Home
  2. HUBS vs UTHR Comparison

HUBS vs UTHR Comparison

Compare HUBS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HubSpot Inc.

HUBS

HubSpot Inc.

HOLD

Current Price

$240.72

Market Cap

11.6B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$571.39

Market Cap

25.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUBS
UTHR
Founded
2005
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.6B
25.1B
IPO Year
2014
1999

Fundamental Metrics

Financial Performance
Metric
HUBS
UTHR
Price
$240.72
$571.39
Analyst Decision
Strong Buy
Buy
Analyst Count
32
14
Target Price
$435.19
$567.57
AVG Volume (30 Days)
1.4M
387.7K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
855.56
13.07
EPS
0.86
27.86
Revenue
$375,612,000.00
$1,483,300,000.00
Revenue This Year
$20.46
$6.39
Revenue Next Year
$16.01
$14.18
P/E Ratio
$256.36
$20.56
Revenue Growth
N/A
2.38
52 Week Low
$187.45
$272.18
52 Week High
$670.54
$607.89

Technical Indicators

Market Signals
Indicator
HUBS
UTHR
Relative Strength Index (RSI) 55.29 55.41
Support Level $209.40 $560.16
Resistance Level $250.14 $593.65
Average True Range (ATR) 12.02 12.17
MACD 3.02 -2.95
Stochastic Oscillator 83.96 33.53

Price Performance

Historical Comparison
HUBS
UTHR

About HUBS HubSpot Inc.

HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: